A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study has been terminated based on a strategic evaluation within the current Pfizer oncology portfolio. This decision is not due to any safety concerns or requests from any regulatory authorities.

Conditions

Advanced Solid Tumors
Metastatic Solid Tumors

Interventions

DRUG: PF-06939999 dose escalation
DRUG: PF-06939999 monotherapy
DRUG: PF-06939999 in combination with docetaxel

Sponsor

Pfizer